BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 9647205)

  • 1. Repertoire analysis of CD8+ T cell responses to minor histocompatibility antigens involved in graft-versus-host disease.
    Friedman TM; Gilbert M; Briggs C; Korngold R
    J Immunol; 1998 Jul; 161(1):41-8. PubMed ID: 9647205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunodominant CD4+ T cell receptor Vbeta repertoires involved in graft-versus-host disease responses to minor histocompatibility antigens.
    Berger MA; Korngold R
    J Immunol; 1997 Jul; 159(1):77-85. PubMed ID: 9200441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vbeta spectratype analysis reveals heterogeneity of CD4+ T-cell responses to minor histocompatibility antigens involved in graft-versus-host disease: correlations with epithelial tissue infiltrate.
    Friedman TM; Statton D; Jones SC; Berger MA; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2001; 7(1):2-13. PubMed ID: 11215694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inter-strain graft-vs.-host disease T-cell responses to immunodominant minor histocompatibility antigens.
    Korngold R; Leighton C; Mobraaten LE; Berger MA
    Biol Blood Marrow Transplant; 1997 Jun; 3(2):57-64. PubMed ID: 9267665
    [TBL] [Abstract][Full Text] [Related]  

  • 5. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
    Berger M; Wettstein PJ; Korngold R
    Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific donor Vbeta-associated CD4 T-cell responses correlate with severe acute graft-versus-host disease directed to multiple minor histocompatibility antigens.
    Jones SC; Friedman TM; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Feb; 10(2):91-105. PubMed ID: 14750075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evolution of responding CD4+ and CD8+ T-cell repertoires during the development of graft-versus-host disease directed to minor histocompatibility antigens.
    Friedman TM; Jones SC; Statton D; Murphy GF; Korngold R
    Biol Blood Marrow Transplant; 2004 Apr; 10(4):224-35. PubMed ID: 15077221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oligoclonal expansion of CTLs directed against a restricted number of dominant minor histocompatibility antigens in hemopoietic chimeras.
    Brochu S; Baron C; Hétu F; Roy DC; Perreault C
    J Immunol; 1995 Dec; 155(11):5104-14. PubMed ID: 7594519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunodominance in the graft-vs-host disease T cell response to minor histocompatibility antigens.
    Korngold R; Wettstein PJ
    J Immunol; 1990 Dec; 145(12):4079-88. PubMed ID: 2258608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin inhibits the generation of graft-versus-host disease- and graft-versus-leukemia-causing T cells by interfering with the production of Th1 or Th1 cytotoxic cytokines.
    Blazar BR; Taylor PA; Panoskaltsis-Mortari A; Vallera DA
    J Immunol; 1998 Jun; 160(11):5355-65. PubMed ID: 9605135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
    Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
    Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lethal graft-versus-host disease in mice directed to multiple minor histocompatibility antigens: features of CD8+ and CD4+ T cell responses.
    Korngold R
    Bone Marrow Transplant; 1992 May; 9(5):355-64. PubMed ID: 1352163
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oligoclonal expansion of T cell receptor V beta 2 and 3 cells in the livers of mice with graft-versus-host disease.
    Chen W; Howell CD
    Hepatology; 2002 Jan; 35(1):23-9. PubMed ID: 11786956
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of immunoregulatory donor T cells in suppression of graft-versus-host disease following donor leukocyte infusion therapy.
    Johnson BD; Becker EE; LaBelle JL; Truitt RL
    J Immunol; 1999 Dec; 163(12):6479-87. PubMed ID: 10586039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
    Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-mediated acute graft-versus-host disease.
    Zhang Y; Louboutin JP; Zhu J; Rivera AJ; Emerson SG
    J Clin Invest; 2002 May; 109(10):1335-44. PubMed ID: 12021249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative importance of CD4+ and CD8+ T cell repertoires in the development of acute graft-versus-host disease in a murine model of bone marrow transplantation.
    Miconnet I; de La Selle V; Bruley-Rosset M
    Bone Marrow Transplant; 1998 Mar; 21(6):583-90. PubMed ID: 9543062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
    Drobyski WR; Majewski D; Ozker K; Hanson G
    J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biased liver T cell receptor V beta repertoire in a murine graft-versus-host disease model.
    Howell CD; Li J; Roper E; Kotzin BL
    J Immunol; 1995 Sep; 155(5):2350-8. PubMed ID: 7650370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD3 epsilon F(ab')2 fragments inhibit T cell expansion in vivo during graft-versus-host disease or the primary immune response to nominal antigen.
    Blazar BR; Jenkins MK; Taylor PA; White J; Panoskaltsis-Mortari A; Korngold R; Vallera DA
    J Immunol; 1997 Dec; 159(12):5821-33. PubMed ID: 9550378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.